The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

BACKGROUND In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed to validate a quantitative algorithm for predicting survival derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) and develop a simplified calculator for everyday clinical use. METHODS Prospectively collected data from patients with newly diagnosed (< 3 months) World Health Organization group I pulmonary hypertension enrolled in the REVEAL Registry were used to validate a predictive algorithm for 1-year survival. Model calibration was evaluated by comparing algorithm-predicted survival with observed Kaplan-Meier estimates for the overall validation cohort and for five risk groups. Similarly, the risk discriminators for the simplified calculator were compared with those of the quantitative algorithm. RESULTS The validation cohort comprised 504 individuals with mean ± SD 6-min walk distance 308 ± 128 m, and 61.5% were functional class III. The proportion of patients surviving 1 year fell within the range predicted by the model (95.1%, 91.5%, 84.6%, 76.3%, and 58.2%, respectively) among patients in the low (predicted survival ≥ 95%), average (90% to < 95%), moderate (85% to < 90%), high (70% to < 85%), and very high (< 70%) risk strata. Predicted and observed 1-year survival were similar across risk stratum, and the c-index indicated good discrimination for both the full equation (0.726) and the simplified risk calculator (0.724). CONCLUSIONS The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

[1]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[2]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[3]  P. Hassoun,et al.  Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. , 2009, Circulation.

[4]  M. Pencina,et al.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.

[5]  M. Mcgoon,et al.  Survival in Pulmonary Arterial Hypertension Parameters in the Prediction of Long-term Integration of Clinical and Hemodynamic , 2010 .

[6]  S. Schneeweiss,et al.  Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. , 2000, Chest.

[7]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[8]  P. Escribano Subías,et al.  Current diagnostic and prognostic assessment of pulmonary Hypertension. , 2010, Revista espanola de cardiologia.

[9]  G. Raskob,et al.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension. , 2008, Mayo Clinic proceedings.

[10]  J. Mir,et al.  Evaluación diagnóstica y pronóstica actual de la hipertensión pulmonar , 2010 .

[11]  Samy Suissa,et al.  Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.

[12]  Z. Jing,et al.  Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. , 2007, Chest.

[13]  L. Abenhaim,et al.  Temporal trends and drug exposures in pulmonary hypertension: an American experience. , 2006, American heart journal.

[14]  G. Raskob,et al.  The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. , 2011, Chest.

[15]  F. Harrell,et al.  Predicting outcome in coronary disease. Statistical models versus expert clinicians. , 1986, The American journal of medicine.

[16]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[17]  R. Speich,et al.  Severe pulmonary hypertension: data from the Swiss Registry. , 2001, Swiss medical weekly.

[18]  S. Suissa,et al.  Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. , 2010, Circulation.

[19]  M. Mcgoon,et al.  Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. , 2011, Chest.

[20]  Sanjiv J. Shah,et al.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.

[21]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[22]  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[23]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[24]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.